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Abstract
Primary graft dysfunction (PGD) remains the leading cause of early mortality post-heart transplantation. Despite improvements
in mechanical circulatory support and critical care measures, the rate of PGD remains significant. A recent consensus statement
by the International Society of Heart and Lung Transplantation (ISHLT) has formulated a definition for PGD. Five years on, we
look at current concepts and future directions of PGD in the current era of transplantation.
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Primary graft dysfunction
Heart transplantation remains the closest resemblance to a
‘cure’ for end-stage heart failure. Worldwide, more than
4000 adults undergo heart transplantation annually [1].
Whilst survival after cardiac transplantation has improved
over the past four decades, primary graft dysfunction (PGD)
is the leading cause of 30-day mortality post-transplant. The
incidence of PGD is yet to be accurately delineated given the
lack of an international consensus regarding its definition.
Reports to date vary widely with respect to diagnostic criteria
and definitions, therefore making incidence and outcomes dif-
ficult to compare between centres and regions. Prior to 2014,
the International Society of Heart and Lung Transplantation
(ISHLT) registry noted a 30-day of 10% in all heart transplants
done since 1982 [2]. The 90-day mortality was 14%. Almost
70% of these deaths were coded as ‘graft failure’ or ‘multi-
organ failure’ for which a large majority would likely consti-
tute contemporary PGD. Here, we provide a comprehensive
overview of PGD in heart transplantation.
Definition
PGD presents as severe ventricular dysfunction of the donor
graft which fails to meet the circulatory requirements of the
recipient in the immediate post-transplant period. It may man-
ifest as either single or biventricular dysfunction with low
cardiac output and hypotension despite adequate filling pres-
sures [3–5]. In 2014, Kobashigawa et al. provided a consensus
definition and grading system based on the modified Delphi
method [6]. This agreement upon a uniform definition allowed
subsequent studies to outline its true incidence and further
explore and identify the potential multifactorial aetiologies
underpinning PGD.
PGD is defined as being a separate entity from secondary
graft dysfunction, which is when a discernible cause for allo-
graft dysfunction is identified. Such causes can include hyper-
acute rejection, graft dysfunction secondary to pulmonary hy-
pertension or a recognised intraoperative complication. The di-
agnosis of PGD is made within 24 h post-transplantation and is
separated into PGD-LV, for PGD affecting the left ventricle or
biventricular failure; and PGD-RV for isolated right ventricular
involvement [6]. A severity scale applies to PGD-LV. For the
mild and moderate categories, it relies on the requirement of
inotropic support with a composite score as described by
Wernovsky et al. (< 10 =mild, ≥ 10 =moderate) alongside ei-
ther using echocardiography to identify ventricular dysfunction
or right heart catheterisation to demonstrate haemodynamic
compromise [7]. For the echocardiography criteria, the left ven-
tricular ejection fraction < 40% is considered diagnostic for
PGD (in the absence of secondary causes). With regard to
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haemodynamic parameters, high filling pressures i.e. a right
atrial pressure (RAP) > 15 mmHg, and pulmonary capillary
wedge pressure (PCWP) > 20mmHg indicate PGD if occurring
in the context of a low cardiac index (CI) (< 2.0 L/min/m2)
lasting at least 1 h. The requirement of an intra-aortic balloon
pump signifies moderate PGD-LV, whereas requirement of ex-
tracorporeal short-term mechanical circulatory support in the
form of extracorporeal membrane oxygenation (ECMO) or
ventricular assist devices (VADs) in any form (percutaneous/
surgical) is diagnostic of severe PGD-LV [6].
PGD-RV does not have a severity scale and is diagnosed
based on the requirement of a right-sided short-term VAD
(RVAD) or right heart catheter measured haemodynamics in
keeping with isolated right-sided dysfunction (RAP >
15 mmHg, PCWP < 15 mmHg, CI < 2.0 L/min/m2, TPG <
15 mmHg and/or pulmonary artery systolic pressure <
50 mmHg) [6].
Previous studies had used the need for mechanical circula-
tory support as a criterion for diagnosis of primary graft dys-
function; however, the timing of initiation of therapy and end-
points differs from these studies, leading to significant varia-
tion in incidence reporting (2.3–32.4%) [4, 8–11]. With an
increasing trend towards utilisation of marginal donor organ
due to increasing waiting list pressures, a resultant reduction
in threshold for initiation of ECMO support in certain patients
to support the graft in the initial phase of reperfusion (first
24 h) may result in an over-estimation of the incidence of
PGD [12]. This is especially true in high-risk recipients with
a significant inflammatory milieu as a result of receiving a
combination of in-hospital inotropic or short- or long-term
mechanical circulatory support pre-transplant.
Pathophysiology of PGD
The donor heart is exposed to amultitude of physiological insults
at four specific time points: brainstem death, hypothermic ischae-
mia, warm ischaemia and ischaemia-reperfusion injury.
Brainstem death
The first insult occurs during declaration of brainstem death in
donation after brainstem death (DBD). Raised intracranial pres-
sure (ICP) invariably is the final pathway in DBD donors in
which case the aetiology of death is usually a result of an intra-
cerebral haemorrhage, hypoxia leading to oedema, inflammation
or a space occupying lesion in the cranium. The cerebral perfu-
sion pressure is usually maintained by homeostatic mechanisms
which result in an increased arterial pressure. Due to the limited
plasticity of the brain within the confines of the cranium, brain
herniation ensues resulting in pontine ischaemia [13]. This causes
a surge in the adrenergic response, resulting in pulmonary and
systemic hypertension which increases the afterload in both ven-
tricles causing myocardial ischaemia. In some patients,
stimulation of baroreceptors results in the classic Cushing’s re-
sponse characterised by hypertension and bradycardia [14, 15].
Vasomotor tone is reduced to the loss of spinal cord sym-
pathetic activity resulting in unopposed vasodilatation, further
reducing preload and indirectly afterload, affecting coronary
blood flow and reducing myocardial perfusion. As a response,
there is an intense release of myocardial noradrenaline imme-
diately after brain death that results in mitochondrial and cy-
tosolic calcium overload to increase contractility to counteract
this unopposed vasodilatation [15]. Pituitary ischaemia may
also occur during brain herniation resulting in significant en-
docrine derangement [16].
These patients are also prone to metabolic disturbances due
to acidosis, hypomagnesaemia or hypokalemia secondary to
mannitol initiation to reduce ICP, catecholamine administra-
tion, all of which contribute to increased myocardial oxygen
demand or reduced myocardial perfusion [16]. This initial
surge may also cause catecholamine depletion leading to a
vicious circle of impaired myocardial oxygenation with in-
creasing myocardial oxygen demand [13].
Early donor management may reduce the deleterious ef-
fects of the abovementioned phenomenon. Early administra-
tion of vasopressors is aimed at reducing the unopposed va-
sodilatation [17]. Methylprednisolone administration has been
shown to reduce lung injury independently from its anti-
inflammatory activity in animal studies as well as reduce ex-
travascular lung water and reduce PCWP in DBD donors [18,
19]. It is also used in conjunction with insulin to ensure
normoglycemia in the donor [20]. The role of thyroid hor-
mone replacement is uncertain during donor management
with current consensus suggesting triiodothyroxine (T3) ad-
ministration only in depleted donors [16, 19, 21, 22].
Hypothermic ischaemia
Despite advancements in normothermic ex vivo perfusion de-
vices, cold storage remains the mainstay of transportation after
organ retrieval. Organ retrieval often has two distinct phases, a
warm phase and a cold phase. The warm phase involves dis-
section of the heart and exposure of the innominate artery and
the two cavae with variations in the degree of dissection de-
pending on whether the lungs are to be retrieved as well. The
retrieval surgeon also palpates the coronary arteries for poten-
tial disease. The aorta is prepared for administration of cold
cardioplegia for commencement of the cold phase.
Depending on the size of the patient and type of cardioplegic
solution administered, the volume of administration may differ.
The retrieval surgeon then performs a left atriotomy by lifting
the heart. Once the aortic cross-clamp is applied, cold
cardioplegia is infused via the aortic root at approximately
4 °C. The retrieval process is completed with the heart placed
in a cold storage container. Cold storage induces hypothermic
arrest of metabolism andmaintains viability during this reduced
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metabolic state, therefore abating cellular swelling and
minimalizing reperfusion injury [23]. At these temperatures,
and with limited oxygenation, the heart switches from aerobic
to anaerobic metabolism. This can have deleterious effects on
the stored organs as ATP is slowly depleted; however, it should
be noted that in the hypothermic state (0–4 °C), there is a 12-
fold decrease in metabolic rate [24]. The overall goal is to
reduce the accumulation of mitochondrial byproducts of metab-
olism such as oxygen free radicals. Cold storage is also based
on the assumption that there is no variation in temperature and
the heart is uniformly cooled. In elderly patients whereby, path-
ologic LV hypertrophy may be noted especially in those with a
clinical history of hypertension this may not be possible, possi-
bly explaining why these hearts are more susceptible to ischae-
mic injury [4, 25]. The length at which the hearts are kept in
cold storage may also play a part in the formation of these free
radicals. Cellular swelling and lactic acidosis occurs in
prolonged cold storage, causing a rise in intracellular H+ ions
[26]. The Na+/H+ exchanger is activated resulting in an increase
in intracellular Na+ which activates the Na+/Ca2+ exchanger
[27, 28]. The final pathway is the accumulation of cytosolic
Ca2+. This will play a major role in the pathogenesis of
ischaemic-reperfusion injury.
Warm ischaemia
On arrival at the recipient centre, the heart is removed from
cold storage and inspected. The period in which the heart is
removed from cold storage or from ex vivo normothermic
perfusion to the final release of the recipient aortic cross-
clamp is termed warm ischaemic time. The heart is exposed
to warmer temperatures which slowly increases its metabolic
rate resulting in increased formation of oxygen free radicals.
In a study byMarasco et al., warm ischaemic time and increas-
ing donor age were independent predictors of early survival,
suggesting an acceleration of the deleterious effects described
during the cold ischaemic phase [29]. Similar findings were
noted by Banner et al., despite a broader definition of warm
ischaemic time termed surgical implant time (i.e. arrival of
heart to theatre to release of recipient aortic cross-clamp).
Ischaemia-reperfusion injury
Ischaemia-reperfusion injury (IRI) is defined as cardiomyocyte
damage secondary tomyocardial restoration of blood flow [30].
On release of the recipient cross-clamp, the donor heart is re-
perfused which leads to further calcium overload. This along-
side the release of oxygen free radicals activates the formation
of mitochondrial permeability transition pores (MPTP) which
are non-specific, thus allow free movement of apoptotic factors
across the cell membrane [31]. This causes a cascade of myo-
cardial damage, causing loss of cardiomyocyte function and
viability; all of which are most pronounced immediately after
reperfusion [32]. Post-conditioning may play a role in attenuat-
ing the effects of IRI by inhibiting MPTP formation.
Cyclosporine A, a known MPTP desensitiser, has been shown
to induce appreciable protection in acute myocardial infarction
[33]. However, a recent meta-analysis failed to show any ben-
efit of cyclosporine A post-infarction [34]. Other forms of pre-
conditioning have also been suggested in an attempt to inhibit
MPTP formation have shown some promise in animal studies
[35–37]. However, larger clinical trials in surgical
revascularisation studies have revealed mixed results with some
studies showing clinical improvements [38] and others showing
minor biochemical improvements with no clinical benefit
[39–43]. The proponents of ischaemic preconditioning have
suggested that the duration of ischaemia in these studies prob-
ably limits the effect of preconditioning with prolonged ischae-
mia showing greater benefit of preconditioning [44]. To date,
no studies have been performed in human heart transplants,
with animal models of orthotopic heart transplants showing
promising results potentially highlighting its benefits in
prolonged ischaemia [45].
Animal studies do however highlight attenuation of IRI
using preconditioning in diabetics [46–48], females [49, 50],
LV hypertrophied hearts [51], obesity [48], hypertensives [52]
and in the elderly [50, 52, 53]; all of which have been noted to
be risk factors for PGD.
Another mechanism of IRI is hypercontracture-mediated
sarcolemmal rupture (HMSR). During the ischaemic phase,
the low cytosolic ATP concentrations are quickly exhausted
resulting in myofibrillar shortening that remains fixed as all
cross-bridges between actin and myosin remain in an attached
state [54]. This causes a moderate contracture with little struc-
tural damage but leads to cytoskeletal defects and increasing
the cardiomyocyte fragility to mechanical damage which is
reversible with early reperfusion [55].
Reperfusion-induced hypercontracture occurs after
prolonged ischaemia. There is greater myofibrillar shortening
and cytoskeletal damage when compared to the ischaemic
phase alone. It causes a marked rise in end-diastolic pressure
with increased ventricular wall stiffness. It is shown to be due
to Ca2+ overload which develops during ischaemia and is
rapidly re-energised, as it would on release of the cross-
clamp [56]. In cellular studies, re-perfused infarcts consist
almost exclusively of contraction band necrosis [56].
Sarcolemmal rupture occurs due to the degradation of struc-
tural proteins like α-fodrin [57] and ankyrin [58], impairing
the Na+/Ca2+ exchanger pumps. Sarcolemmal rupture also
results in increasing Na+ influx into cardiomyocytes via gap
junctions and may propagate to adjacent cells [59].
Donation after circulatory death
Donation after circulatory death (DCD) provides a different
set of insults to the donor heart. The heart is placed in a
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hypoxemic and hypercarbic environment following with-
drawal of life support [60]. This causes pulmonary vasculature
constriction, with increased pulmonary vascular resistance im-
posed on the right heart [61]. Although the catecholamine
surge of brainstem death is not present, the hypoxemic envi-
ronment induces an adrenergic response. This quickly de-
pletes the myocardial energy stores—leading to circulatory
arrest. A mandatory standoff period ensues as part of the
guidelines for declaration of circulatory death [62]. The heart
is exposed to a period of warm ischaemic time that is present
until the institution of either normothermic regional perfusion
(NRP) or ex vivo normothermic perfusion using the Organ
Care System device (TransMedics Organ Care System
(OCS), Andover, MA, USA) [63].
This prolonged ischaemic period causes intracellular acido-
sis which causes activation of the Na+/H+ exchanger in a path-
way similar to the warm ischaemic period described above,
with a net result of an accumulation of intracellular Ca2+ and
follows the ischaemic-reperfusion pathway on reperfusion.
Recipient factors
Some recipient factors may also predispose a patient to PGD.
Recipients, especially patients who have been on inotropic
support and mechanical devices, have activation of their sys-
temic inflammatory response, which causes intense vasodila-
tion and therefore lowering of the systemic vascular resis-
tance. The net result is a hypotensive state despite adequate
filling and a high cardiac output that is refractory to vasopres-
sor support [64]. The exact pathogenesis of this is poorly
understood to date, some mechanisms have been postulated.
Vasodilation is believed to be caused by the unopposed acti-
vation of vascular smooth muscle adenosine triphosphate-
sensitive potassium channels (KATP channels). Endogenous
nitric oxide, a potent vasodilator, is also implicated in the
pathogenesis alongside vasopressin deficiency [65].
Prolonged ischaemic time has been shown in previous
studies to correlate with complications occurring after cardio-
pulmonary bypass [64]. This association is thought to be due
to the summative effect of the exposure of blood to synthetic
surfaces of the cardiopulmonary bypass circuit which poten-
tiates a cascading inflammatory response. This in turn could
explain the increased incidence in recipients on advanced me-
chanical circulatory support (ECMO or Short-Term VAD).
The ischaemic time may also be prolonged in some patients
whereby careful dissection is necessitated following a previ-
ous sternotomy, highlighting the importance of communica-
tion with the retrieval team to potentially delay the retrieval
procedure to minimise ischaemic time [66].
Another pathogenic mechanism that has been suggested in
the past is recipient pulmonary hypertension. The donor heart
in its ischaemic state is exposed to a relatively high pulmonary
vascular resistance, giving rise to right-sided heart failure. Due
to the poor adaptability of the right ventricle to a sudden
change in vascular resistance, biventricular dysfunction en-
sues due to a reduced left-sided preload, thereby reducing
coronary perfusion and end organ perfusion in the systemic
circulation [67]. This however is currently termed secondary
graft dysfunction and is beyond the scope of this review.
Risk factors for PGD
There are several risk factors that have been suggested that
may contribute to PGD. These include donor factors, recipient
factors and procedural factors.
Donor factors
Donor age Avtaar Singh et al. (2018) highlighted donor age to
be a significant risk factor on multivariate analysis. This may
have been due to the poorer tolerance for long ischaemic times
in hearts from older donors. They highlighted an odds risk of
20% for each decade increment in donor age. A similar finding
was noted by Russo and colleagues [68]. They noted that in
younger donors, there was not significant correlation between
ischaemic time and survival. However, as the donor age in-
creased, there was a statistically significant correlation between
ischaemic times and survival in donor ages > 20. Other studies
have also shown a direct correlation between donor age and low
cardiac output states post-operatively, which were likely PGD,
however were not characterised as such due to the lack of a
definition at the time of publication [69–72].
Gender mismatch Female-donor to male-recipient gender mis-
match is a risk factor for PGD. The exact mechanism is poorly
understood as this persisted despite organ size matching. Male-
donor to female-recipients did not result in an increased PGD
rate. Gender-mismatched organs also had a poorer survival at
up to 5 years. In liver transplantation, recipients had poorer graft
survival in female-donor/male-recipient cohorts compared with
other donor-recipient gender groups despite adjustment for do-
nor risk factors and recipient variables [73]. The role of H-Y
minor histocompatibility antigens has been implicated. Several
haemotopoetic stem cell studies have shown an increased re-
lapse rate in patients undergoing stem cell transplants in female-
donor/male-recipient cohorts [74, 75].
Cause of death in the donor Intracranial haemorrhage is the
most common cause of death for DBD donors in the UK. One
study showed increased PGD rates in organs retrieved from
donors with intracranial haemorrhage compared to donors
with traumatic cause of death [76]. The exact mechanism is
not clear, although it is thought to be due to a prolonged
exposure to the catecholamine surge [76]. Animal studies
have shown a direct correlation between increased intracranial
pressure and worsening myocardial function [15, 77]. Avtaar
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Singh et al. highlighted intracranial haemorrhage as a risk
factor on the unadjusted analysis although it was not present
during multivariate analysis. Another study showed an asso-
ciation with early mortality with a lower survival to discharge
rate in patients transplanted with hearts from donors with
atraumatic intracranial haemorrhage [78].
Donor left ventricular hypertrophy Donors with hypertension
often have a degree of left ventricular hypertrophy (LVH).
This is more apparent across Europe where the average age
of the donor is older compared to North America [1]. The use
of donors with LVH has resulted in mixed results with some
centres having favourable results [25, 79–82] but others
reporting an increased incidence of early graft failure or poorer
survival [83–85]. The reason for the varying results is likely
due to the association of LVH to age, which is an independent
predictor of PGD. Hypertrophied hearts with associated hy-
pertension are more susceptible to ischaemic injury [86].
Therefore, the ischaemic time for donors with hypertrophied
hearts should be kept to a minimum. The Harefield team re-
ported their experience in using marginal donors with mild
LVHwith normothermic ex vivo perfusion [87]. They showed
promising short-term outcomes when utilising marginal hearts
with continuous normothermic perfusion using the OCS de-
vice. The ISHLT guidelines also cites level of evidence C for a
class IIa recommendation stating that Bit would seem appro-
priate to use hearts from donors with LVH and LV wall thick-
ness <14 mm provided that it is not associated with ECG
findings of LVH^ [88].
Donor inotropic requirement Inotropic support is sometimes
needed during the donor organ retrieval process due to the
depletion of catecholamine and/or a systemic inflammatory
phenomenon as described above. Noradrenaline use can cause
left ventricular dysfunction in the absence of brain death [89].
It also has a dose-dependent detrimental effect on the right
ventricle in DBD donors [90–92]. The use of vasopressin
and terlipressin is currently recommended as first-line treat-
ment to reduce the noradrenaline requirement [93]. It treats
two conditions which occur commonly in DBD donors, neu-
rogenic diabetes insipidus and reduction in systemic vascular
resistance [94]. Venkateswaran et al. showed that vasopressin
use could result in the elimination or reduction of noradrena-
line use in more than 50% of donors [95].
Recipient factors
Pre-operative mechanical circulatory support Pre-operative
recipient ECMO/VAD usage has also been linked to PGD
post-operatively [4, 90, 96, 97]. Several factors have been
suggested as potential causes which have been discussed un-
der the pathophysiology section above.
A recent study by Truby and colleagues highlighted the
role of continuous flow LVAD (CF-LVAD) in recipients as a
risk factor for severe PGD [98]. This is of particular interest as
CF-LVADs have contributed significantly to the growth and
success of mechanical circulatory support for advanced heart
failure for BTT and as destination therapy. CF-LVADs also
account for more 95% of VAD implants currently [99].
Forty-five out of 56 (80.4%) patients with severe PGD were
bridged to transplant (BTT) using CF-LVADs in Truby’s study
[98]. It should be noted however there were significant other
contributary factors as the severe PGD patients were older,
had a higher percentage of previous amiodarone exposure,
had higher creatinine levels, spent longer time on the waiting
list and had a higher CVP/PCWP ratio which is possibly in-
dicative of subclinical right ventricular dysfunction.
Recipient diabetes mellitus
The role of recipient diabetes as a predictor of PGD is evident
in multiple studies [92]. The results of Avtaar Singh et al.
however show that the 95% confidence interval (0.9993–
4.1720) crosses the boundary of no effect for diabetes.
Segovia’s study was unable to account for recipient diabetes
as a predictor of PGD when using robust statistical analysis
(overfitting of regression models [100]. However, recipient
diabetes seems to be a predictor of graft loss within and be-
yond the first-year post-transplant [101]. This may be due to
direct glucose-mediated endothelial damage, oxidative stress
from superoxide overproduction and production of advanced
glycation end-products, which may result in changes in endo-
thelial permeability, excessive vascular protein deposition and
altered blood flow. Taghavi et al. revealed diabetic recipients
were older and would more likely receive organs from diabet-
ic donors who were who themselves were more often females
and older [102].
Recipient age Several studies have associated advancing re-
cipient age with PGD and mortality [90, 92]. A risk prediction
model assessing in-hospital mortality for post-heart transplant
patients included recipient age but utilised it as a categorical
variable. The c-statistic of less than 0.7 however suggested
poor performance [103]. ISHLT registry data also highlighted
advancing recipient age with having slightly higher long-term
mortality. This may probably reflect the higher incidence of
comorbidities such as hypertension and diabetes in this cohort
of patients as well [104]. Some studies have attributed this to
the increased fatal infection rate in the elderly [105, 106].
Recipient re-sternotomy A recipient re-sternotomy indicates
previous surgery, most commonly for durable ventricular as-
sist device implantation, previous congenital cardiac surgery
or previous coronary bypass or valvular surgery [107]. The
dissection process in recipient who has undergone a previous
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sternotomy often is more complex and hazardous with the
potential for significant injury [108]. Recipient re-
sternotomy has been linked to an increased risk of severe
PGD in a recent study. A similar study showed that patients
with prior sternotomies had an almost threefold increase for
PGD risk [109]. The increased technical difficulty of the sur-
gery may result in longer ischaemic times and is associated
with higher rates of blood transfusion and subsequent need for
reoperation for bleeding [109–111]. Patients with prior
sternotomies were also more likely be older [109] and have
spent longer time on the waiting list [109], possibly indicating
durable VAD implantation [110] in these patients as a bridge
to candidacy/transplantation.
Recipient pre-operative amiodarone therapyAmiodarone is a
class III antiarrhythmic used for a variety of arrhythmias in-
cluding both ventricular, supraventricular and atrial tachyar-
rhythmias. Its mechanism of action is primarily by prolonging
the refractory period myocardium. Arrhythmias are highly
prevalent in advanced heart failure patients [112]. The evi-
dence regarding PGD and the use of amiodarone in recipients
appears to be conflicting. Studies have shown that patients
who had received amiodarone before transplantation had sig-
nificantly lower heart rates post-transplantation [113, 114],
required atrial pacing for a longer time after transplantation
[113] but had no increased inotropic requirements [113] and
no increased mortality post-operatively [113–115]. Other
studies have indicated a dose-dependent [116] or duration-
dependent [117] link between amiodarone use and PGD
post-transplant.
Procedural factors
Ischaemic time In DBD donations, the ischaemic time consists
of the placement of the donor aortic cross-clamp till the release
of the recipient aortic cross-clamp [118]. For DCD donations,
the ischaemic time is possibly underestimated with a period of
functional warm ischaemia (starting when systolic blood pres-
sure is less than 50 mmHg) till the heart is re-perfused on an
ex vivo perfusion device (OCS) [63]. A second period of
ischaemia ensues from removal of the heart from the OCS till
release of the aortic cross-clamp from the recipient.
Cold ischaemic time consists of the time spent in cold
storage and warm ischaemia ensues once the heart is removed
from cold storage or the OCS rig till release of the aortic cross-
clamp. Prolonged ischaemic time is associated with an in-
creased rate of PGD [4, 29, 92, 119]. Banner et al. noted that
longer ischaemia time was a risk factor for 30-day mortality
after heart transplantation. They also noted that the surgical
implant time (i.e. warm ischaemic time) was an independent
risk factor for 30-daymortality [120]. Avtaar Singh et al. noted
that warm ischaemic time/implant time to be a significant
independent predictor of ISHLT defined PGD. The direct
ischaemic insult of warm ischaemia is explained in the path-
ophysiology above. Marasco et al. also noted found that
poorer survival with a warm ischaemia time (WIT) of >
80 min [29]. Ischaemic time is also closely related to donor
age. Older donor organs are more susceptible to ischaemic
injury compared to younger donor organs [68, 121].
Cardiopulmonary bypass time Prolonged cardiopulmonary
bypass (CPB) duration independently predicts post-operative
morbidity and mortality after general cardiac surgery [122].
Kirklin and colleagues alluded to a systemic inflammatory
response following CPB [123]. Themechanism of injury from
CPB and ischaemic-reperfusion of the myocardium is similar,
both producing a hyperdynamic circulatory state due to a low
systemic vascular resistance, platelet and coagulation factor
dysfunction, inflammatory pathway activation triggered by
leucocytes and endothelial cells and finally cytokine release
and formation of oxygen free radicals [124]. It is also linked to
an increased blood product requirement which is associated
with both infection and ischaemic post-operative morbidity,
increased hospital stay, increased early and late mortality and
increased hospital costs [125–127]. Therefore, prolonged
CPB time may contribute to the worsening of the ischaemic
injury caused by PGD.
Size mismatch The size of the donor graft has many implica-
tions on the recipient. It is a powerful predictor of survival
recipients receiving undersized grafts having an increased 1-
year mortality, and a 36% increased mortality within the first
30 days [128]. Smits showed inferior survival in donors who
were undersized by more than 20% using data from the
Eurotransplant database [129]. This study however also
showed an inferior survival amongst gender-mismatched do-
nors, which were more likely to be undersized in female do-
nors to male recipients. Patel et al. refuted the findings in an
analysis of the UNOS database, suggesting increased pulmo-
nary resistance as a confounder [130]. Another analysis of
the UNOS database several years later concluded that
donor/recipient BMI ratio < 0.75 was associated with in-
crease in post-transplant mortality in univariate analysis
but not in multivariate analysis, highlighting gender mis-
match as a confounder [131]. Other multi-institutional
studies have also highlighted donor-recipient weight dif-
ference to be significant, but only in older grafts which
were gender mismatched [132]. Jayarajan and colleagues
noted that donor weight mismatching by up to 40% had
no bearing on outcome in non-gender mismatched pa-
tients [133]. The significance of size mismatching is
hard to elucidate from studies but smaller single-centre
data suggests poorer outcomes such as an increased
length of stay [134] and increased LV hypertrophy
[135]. The direct link between PGD and size mismatch
however remains elusive.
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Investigations and biomarkers
The current definition for PGD is based on the treatment op-
tions utilised. Several biomarkers have been suggested as po-
tential predictors of PGD, although to date none are used in
routine care.
Inflammatory markers
The pro-inflammatory state accompanying PGD supports the
use of inflammatory markers as potential predictive bio-
markers. Tumour necrosis factor-α (TNF-α), interleukin-6
(IL-6), neutrophils and procalcitonin (PCT) have all been sug-
gested as potential biomarkers.
TNF-α Tumour necrosis factors are produced by lymphocytes
and macrophages that cause cell lysis [136]. TNF-α has been
implicated in the pathogenesis of numerous inflammatory
conditions including arthritis [137], asthma, chronic obstruc-
tive pulmonary disease (COPD), acute respiratory distress
syndrome (ARDS) [138], myocarditis [139] and congestive
heart failure [140].
Birks and colleagues noted an increased expression of
TNF-α in unused donor hearts due to poor function and com-
pared them with donors with good ventricular function (used
donors) and patients with advanced heart failure (HF) [141].
In lung transplantation, a recent study highlighted the role of
intravascular donor monocytes in the pathophysiology of IRI
and PGD in lungs [142]. Another group showed reduction in
PGD rates post-lung transplantation after leukocyte depletion
[143]. Venkateswaran et al. highlighted poorer biventricular
function in donors with elevated levels of TNF-α using serum
immunoassays [144].
A Brazilian group showed recipients receiving grafts from
donors expressing lower concentrations of plasma soluble tu-
mour necrosis factor receptors 2 (sTNFR2) and IL-6, required
more inotropic support post-transplantation [145].
IL-6 Interleukin 6 (IL-6) is produced in response to infections
and tissue injuries by stimulation of acute phase responses. It
bridges the adaptive and innate immune responses and plays a
major role in autoimmune conditions [146, 147]. Birks et al.
noted IL-6 mRNA expression was 2.4-fold higher in the un-
used donor hearts than in those used for transplantation, with
levels almost five times higher than in the potential recipients
with advanced heart failure [141]. The used donor hearts had
an almost twofold increase of IL-6 mRNA levels compared to
the recipients. These findings were also noted by Plenz and
colleagues, who noted a significant rise in IL-6 and IL-6 re-
ceptors in DBD donors, comparable to patients with advanced
heart failure in comparison with a control group not compro-
mised by the sequelae of brain death. This may explain the
close association of elevated IL-6 serum levels and acute al-
lograft dysfunction in the early post-operative period [148].
IL-6 was also shown to be associated with PGD post-lung
transplantation. The serum and bronchioalveolar lavage con-
centrations of IL-6 were higher in transplant recipients with
PGD than those without [149].
Animal models have shown that ischaemic cardiac
myocytes in watershed viable zones of a myocardial infarction
exhibited reperfusion-dependent expression of IL-6 mRNA
after reperfusion [150, 151].
Procalcitonin Procalcitonin (PCT) is a 116-amino acid peptide
that has an approximate molecular weight of 14.5 kDa and
belongs to the calcitonin (CT) superfamily of peptides [152].
It is a biomarker that exhibits greater specificity than other pro-
inflammatory markers in identifying patients with sepsis [152].
In transplantation, PCT was used to differentiate bacterial
infection from organ rejection. PCT levels are elevated in both
conditions but significantly higher in the presence of infec-
tions [153, 154]. It has important prognostication value in
heart transplantation with low levels signifying an uneventful
course, and higher value indicating an increased mortality in
the early post-operative period [155]. Venkateswaran et al.
noted that elevated donor serum PCT levels were associated
with poorer donor cardiac index and worse biventricular func-
tion despite early donor management during pre-retrieval op-
timisation [144]. The authors demonstrated that pre-
optimisation baseline PCT levels of less than or equal to
2 ng mL−1 was a potentially useful tool in predicting the
end-management heart usability for transplantation. Similar
findings were noted byWagner and colleagues with increased
30-day mortality and early graft dysfunction in hearts utilised
from donors with elevated PCT levels [156]. The increased
early graft failure rate was also noted in renal [157], but not in
liver [158] or lung transplantation [159].
Neutrophil to lymphocyte ratio Both NLR and platelet to
lymphocyte ratio (PLR) have been used as markers of inflam-
mation with prognostic value in coronary artery disease [160,
161] and other conditions. Neutrophil to lymphocyte ratios
(NLR) have been shown to be independently related to mor-
tality in patients hospitalised for acute heart failure with LVSD
[162]. Implantation of LVAD in patients with heart failure
showed reversibility of NLR which reflects the reversal of
various HF-mediated inflammatory processes [163].
A group in Argentina studied the relationship between the
two ratios and survival after heart transplantation [164]. They
noted NLR (baseline and at 6 h) to be a good predictor of early
mortality post-heart transplantation but not PLR. The number
of patients in the single-centre study was relatively small (n =
111). A Polish single-centre study noted similar findings in
their renal transplant cohort, with NLR showing good predic-
tive value of early graft dysfunction [165]. Another recent
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study showed good correlation between NLR and survival
after ECMO institution in non-transplant patients presenting
with cardiogenic shock [166]. However, patients in the in-
creased NLR ratio arm of this study were also significantly
older with a higher blood urea nitrogen levels.
Troponin
Cardiac troponins are regulatory proteins that control the
calcium-mediated interaction between actin and myosin. The
measurements of serum cardiac troponin I (cTnI) and cardiac
troponin T (cTnT) have shown to be sensitive and specific
markers of myocardial damage [167].
The pathophysiology of brainstem death results in a cate-
cholamine storm that is believed to cause transient myocardial
ischaemia and injury [168]. Circulating cardiac troponin con-
centrations may therefore be elevated in the donor.
Several studies however have shown that elevated serum
troponin levels in donors may predict adverse outcomes post-
transplantation. Increasing cTnT levels have been shown to be
associated with a reduction in left ventricular ejection fraction
in the donor [169]. Potapov et al. showed in a single-centre
observational study that increased donor cTnT levels were
associated with an increased rate of early allograft failure
[170]. They showed a similar association with PCT indicating
a coexistent pro-inflammatory state in these donors. PCT and
cTnT levels however showed poor specificity. There was also
no correlation between PCTand cTnT values and there was no
significant interaction between the two markers using a logis-
tic regression model (P = 0.28). Vijay et al. conducted a sim-
ilar study, using endomyocardial biopsy proven rejection at
1 year as the primary endpoint. They noted a linear correlation
between grade of rejection at 1-year and donor cTnT levels
[171]. Another study by Potapov et al. showed an association
between increasing cTnI levels in donors to early graft dys-
function post-transplantation [172].
In donors with subarachnoid haemorrhages, cTnI was a
good indicator for left ventricular dysfunction, however this
was reversible, and did not affect outcomes post-transplant
[173, 174]. Boccheciampe et al. noted that cTnI values in do-
nors were not associated with PGD or post-transplant survival
[175]. Other larger studies of donor serum troponin have shown
no association between elevated levels and PGD [176, 177].
A recent study of cTnI in the preservation solution
(University of Wisconsin solution and Custodiol) during
transportation of heart grafts however showed that elevated
cTnI (scaled to the corresponding LV mass) was predictive
of post-transplant PGD [178]. They also noted there was poor
correlation between preservation fluid cTnI levels and donor
serum cTnI levels. They raised the possibility that incomplete
myocardial preservationmay play a role in PGD pathogenesis.
However, there were only 43 patients in the study, and only
ischaemic time was noted to be a predictor of PGD in their
logistic regression model.
Brain natriuretic peptide/N-terminal pro–B-type natriuretic
peptide
Brain natriuretic peptide (BNP) and its amino-terminal pro-
fragment, N-terminal pro–B-type natriuretic peptide (NT-
proBNP) are commonly used for diagnosis and prognostica-
tion in heart failure [179, 180]. They are released by the myo-
cardium in response to increasing ventricular wall stress [181].
They have been shown to correlate well with ventricular dila-
tion [181], adverse remodelling [182] and death after acute
myocardial infarction [183]. Dronavalli et al. showed that el-
evated NT-proBNP correlate well to poor echocardiographic
and haemodynamic findings of cardiac function in potential
DBD donors [184]. Vorlat et al. linked increased BNP levels
to a lower cardiac output post-transplant and a prolonged hos-
pital stay [185]. They noted that a donor serum BNP of >
160 pg/mL had 89% accuracy to predict poor cardiac perfor-
mance in the recipient (cardiac index < 2.2 L/min/m2). The
authors however could not show a correlation between post-
operative inotropic support and BNP levels.
Others
SWItch/sucrose non-fermentable, a matrix-associated, actin-
dependent regulator of chromatin subfamily a-like 1 SWItch/
sucrose non-fermentable, a matrix-associated, actin-
dependent regulator of chromatin subfamily a-like 1
(SMARCAL1) is an intracellular protein that acts as a DNA-
dependent ATPase involved in transcription, DNA repair and
chromatin dynamics [168]. Aharinejad et al. noted that elevat-
ed serum SMARCAL1 levels in their cohort of 336 donors
were predictive of recipient PGD [186]. In addition,
SMARCAL1 levels correlated well with survival at 3 months,
1-year and 5-year survival. Using a donor serum cutoff of ≥
1.25 ng/mL, they demonstrated a 96% sensitivity and 88%
specificity for predicting PGD. Pre-and post-aortic donor
cross-clamp serum SMARCAL1 concentrations were the best
markers of PGD risk. To date, no other validation studies have
been performed.
Donor myocardial hypoxia-inducible factor-1α Hypoxia-in-
ducible factor (HIF)-1 is a heterodimeric α, β transcription
factor that mediates tissue responses to hypoxia [187].
Aharinejad et al. performed a series of assays using 857 donor
LVmyocardial biopsies obtained before and after aortic cross-
clamping in the donor, and at 10, 30 and 60 min following
reperfusion [188]. In the cDNA array, only HIF-1α mRNA
expression after aortic cross-clamping in donors and at 10 min
following the release of the aortic cross-clamp in the recipient
were significant predictors of PGD. The authors hypothesise
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that the release of cytokines and inflammatory chemokines
activated by ischaemia and reperfusion injury reach the
highest peaks prior to cross-clamping and just after reperfu-
sion. Other studies have demonstrated the protective signal-
ling of HIF-1 against ischaemia-reperfusion injury in the heart
[189, 190]. To date however, there have been no further stud-
ies linked HIF-1α to PGD.
Serum exosome proteomics Several published abstracts
have highlighted the role of serum exosome proteomic
analysis in the recipient as a potential biomarkers for
PGD [191, 192]. Giangreco et al. noted that pre-
transplant serum exosome analysis revealed an inflamma-
tory phenotype and complement activation in patients
who later developed PGD which could be identified by
the absence or presence of the biomarkers alone. Fine
et al. showed this could be further used to differentiate
patients who would later develop PGD-RV from PGD-LV.
In their study, significant upregulation of angiotensinogen
(AGT) and adiponectin (ADIPOQ) signalling pathways
were noted in the PGD-LV group whereas hepatic growth
factor activator (HGFAC) and insulin-like growth factor-
binding protein 3 (IGFBP3) pathways were both upregu-
lated in the PGD-RV group. The significance of these
findings may hopefully shed light into the pathogenesis
of PGD in the near future.
Prevention of PGD
A single administration of cold flush preservation fluid re-
mains the gold standard for myocardial protection during
transplantation. It confers reliable protection for a limited
amount of ischaemic time in young donor hearts [6]. The
increasing use of extended criteria donors however necessi-
tate more aggressive protection strategies to attenuate the
ischaemic effects on hearts. In a study conducted by the
Hamburg group, they noted that the use of a leukocyte de-
pleting filter alongside additional regular antegrade admin-
istration of Buckberg cold blood cardioplegia in intervals of
20 min resulted in a reduction of PGD rates [193]. Similar
findings were noted by a group from the Czech Republic,
utilising continuous cold blood cardioplegia followed by
controlled reperfusion of warm blood [194]. The Glasgow
group utilised a similar variation with continuous antegrade
perfusion in a contemporary cohort of patients, resulting in a
significant reduction in PGD rates compared to a historical
group of patients and the national UK cohort [195]. The
exact mechanisms by which additional cardioplegia admin-
istration reduces PGD remain uncertain. It may play a
role in pre-conditioning, mitigating the impact of reper-
fusion or preventing generation and propagation of in-
flammatory pathways [196].
Treatment and management of PGD
Treatment of PGD thus far is still primarily supportive care. In a
consensus statement by Kobashigawa et al., the treatment and
management of PGD across five high volume transplant centres
were evaluated. PGD is initially managed by using inotropic
support using catecholamines and phosphodiesterase inhibitors.
The most common escalation therapy follow inotropic use is
using an intra-aortic balloon pump. Following this, advanced
mechanical support is initiated which is usually directed by the
expertise of the transplant units themselves. The most common
mode of support is extracorporeal membranous oxygenation
with both central and peripheral cannulation strategies utilised.
The heart should be allowed to eject to prevent stasis and
thromboembolic complications.
For primary RV-PGD, nitric oxide may be used to reduce
the pulmonary vascular resistance. Following a period of sup-
port on ECMO, a short-term ventricular assist device is then
implanted depending on the level of support needed (LVAD,
RVAD, BiVAD ± oxygenator, total artificial heart). Where
possible, the patient is then re-evaluated for a redo-
orthotopic heart transplantation.
Levosimendan
Levosimendan is a calcium sensitising agent and inodilator
which increases cardiac contractility. Its primary mode of ac-
tion is by increasing the sensitivity of troponin-C to calcium
during systole thereby increasing cardiac performance without
increasing myocardial oxygen consumption. It also reduces
peripheral vascular resistances by opening of adenosine
triphosphate–dependent K+ channels [197]. It was initially
used for treatment of cardiogenic shock post-acute myocardial
infarction [197]. However, SURVIVE, a multicentre RCT
evaluating levosimendan vs dobutamine in acute decompen-
sated heart failure, revealed no differences in survival out-
comes between the two groups [198].There was an initial
reduction in plasma B-type natriuretic peptide level in patients
in the levosimendan group compared with patients in the do-
butamine group. Florian Weis and colleagues report a case
series of 12 patients with PGD who received 0.1 μg/kg/min
levosimendan for PGD with a centre-specific definition of
LVEF < 30% on transesophageal echocardiogramwith a com-
bination of adrenaline > 0.1 μg/kg/min and the milrinone >
0.3 μg/kg/min [199]. Eleven of the 12 patients survived be-
yond 30 days, with significant reductions in inotropic support
without requiring mechanical circulatory support. However,
follow-up studies by the same group showed significantly
lower 1-year and 3-year survival rates [200].
The inotropic effects of levosimendanmay often take hours
to develop, which may be offset by its potent vasodilation
capacity [201]. It may however also play a role in protecting
cardiomyocytes against ischaemic/reperfusion injury by
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activating adenosine triphosphate-sensitive potassium chan-
nels in mitochondria as shown by numerous studies although
to date, no studies have been done on pre-or post-conditioning
in a heart transplant setting [202–206].
Plasmapheresis
Plasmapheresis is a process by which whole blood is passed
through a filter to separate the plasma components from the
larger cellular components of red blood cells, white blood
cells and platelets [207]. Its use in transplantation was primar-
ily for hyperacute or acute humoral rejection, whereby adjunc-
tive therapeutic plasma exchange has been used alongside
immunosuppression and intravenous immunoglobulins to im-
prove survival of incompatible organs compared to compati-
ble organs [208]. Plasmapheresis rapidly reduces the circulat-
ing antibodies and thereby improves cardiac function [209].
Plasmapheresis has been used for primary allograft dysfunc-
tion after liver transplantation with encouraging results [210,
211]. A study by a group in Taiwan revealed treatment with
pulsed steroid and plasmapheresis improved the ejection frac-
tion and NYHA status of > 70% of the patients treated [212].
However, the definitions of PGD in this cohort were not dis-
cernible from acute rejection due to the study methodology
and lack of biopsy-proven rejection at the time of treatment as
treatment was started empirically in all 35 patients who were
in NYHA functional class III or IV requiring pharmacological
or mechanical circulatory support. The Cedars-Sinai Heart
Institute group performed a similar study in patients with se-
vere PGD. In their cohort of 15 patients, 66% of whom
underwent plasmapheresis post-transplantation had signifi-
cantly improved outcomes compared to the 33% of severe
PGD patients who did not. They concluded that the potential
role of inflammatory molecule depletion in these patients may
play a role in the pathophysiology of PGD [213]. The exact
role of plasmapheresis in PGD is still speculative and may
potentially be clearer with ongoing research.
Conclusion
PGD is the leading cause of early morbidity and mortality
following heart transplantation. It is thought to be multifacto-
rial in origin and several risk factors implicated. The search for
an accurate biomarker however remains elusive. Treatment
options to date remain supportive with no definitive pharma-
cological agents identified as of yet. Plasmapheresis may have
a role in depletion of inflammatory chemokines and cytokines
for treatment of PGD.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya
AY, Levvey BJ et al (2017) The Registry of the International
Society for Heart and Lung Transplantation: thirty-fourth adult
heart transplantation report; focus theme: allograft ischemic time.
J Heart Lung Transplant 36(10):1037–1046
2. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden
C, Christie JD et al (2013) The Registry of the International
Society for Heart and Lung Transplantation: thirtieth official adult
heart transplant report—2013; focus theme: age. J Heart Lung
Transplant 32(10):951–964
3. Segovia J, Pulpón LA, Sanmartín M, Tejero C, Serrano S, Burgos
R et al (1998) Primary graft failure in heart transplantation: a
multivariate analysis. Transplant Proc 30(5):1932
4. Russo MJ, Iribarne A, Hong KN, Ramlawi B, Chen JM,
Takayama H et al (2010) Factors associated with primary graft
failure after heart transplantation. Transplantation. 90(4):444–450
5. Iyer A, Kumarasinghe G, Hicks M, Watson A, Gao L, Doyle A
et al (2011) Primary graft failure after heart transplantation. J
Transplant 2011:175768
6. Kobashigawa J, Zuckermann A, Macdonald P, Leprince P,
Esmailian F, Luu M et al (2014) Report from a consensus confer-
ence on primary graft dysfunction after cardiac transplantation. J
Heart Lung Transplant 33(4):327–340
7. Wernovsky G, Wypij D, Jonas RA, Mayer JE Jr, Hanley FL,
Hickey PR et al (1995) Postoperative course and hemodynamic
profile after the arterial switch operation in neonates and infants. A
comparison of low-flow cardiopulmonary bypass and circulatory
arrest. Circulation. 92(8):2226–2235
8. Dronavalli VB, Rogers CA, Banner NR (2015) Primary cardiac
allograft dysfunction-validation of a clinical definition.
Transplantation. 99(9):1919–1925
9. D'Alessandro C, Aubert S, Golmard JL, Praschker BL, Luyt CE,
Pavie A et al (2010) Extra-corporeal membrane oxygenation tem-
porary support for early graft failure after cardiac transplantation.
Eur J Cardiothorac Surg 37(2):343–349
10. Oto T, Excell L, Griffiths AP, Levvey BJ, Bailey M, Marasco S
et al (2008) Association between primary graft dysfunction among
lung, kidney and heart recipients from the same multiorgan donor.
Am J Transplant 8(10):2132–2139
11. IbrahimM, Hendry P, Masters R, Rubens F, Lam BK, RuelM et al
(2007) Management of acute severe perioperative failure of cardi-
ac allografts: a single-centre experience with a review of the liter-
ature. Can J Cardiol 23(5):363–367
12. Chew HC, Kumarasinghe G, Iyer A, Hicks M, Gao L, Doyle A
et al (2014) Primary graft dysfunction after heart transplantation.
Curr Transplant Rep 1(4):257–265
13. Gordon JK, McKinlay J (2012) Physiological changes after brain
stem death and management of the heart-beating donor. Contin
Educ Anaesth Crit Care Pain 12(5):225–229
14. Dictus C, Vienenkoetter B, Esmaeilzadeh M, Unterberg A,
Ahmadi R (2009) Critical care management of potential organ
donors: our current standard. Clin Transpl 23(Suppl 21):2–9
15. Shivalkar B, Van Loon J, Wieland W, Tjandra-Maga TB, Borgers
M, Plets C et al (1993) Variable effects of explosive or gradual
increase of intracranial pressure on myocardial structure and func-
tion. Circulation. 87(1):230–239
16. Souter MJ, Eidbo E, Findlay JY, Lebovitz DJ, Moguilevitch M,
Neidlinger NA et al (2017) Organ donor management: part 1.
Heart Fail Rev
Toward a consensus to guide anesthesia services during donation
after brain death. Semin Cardiothorac Vasc Anesth 22(2):211–222
17. Rosendale JD, Kauffman HM, McBride MA, Chabalewski FL,
Zaroff JG, Garrity ER et al (2003) Hormonal resuscitation yields
more transplanted hearts, with improved early function.
Transplantation. 75(8):1336–1341
18. Meers CM,Wauters S, Verbeken E, Scheers H, Vanaudenaerde B,
Verleden GM et al (2011) Preemptive therapywith steroids but not
macrolides improves gas exchange in caustic-injured donor lungs.
J Surg Res 170(1):e141–e1e8
19. Venkateswaran RV, Patchell VB, Wilson IC, Mascaro JG,
Thompson RD, Quinn DWet al (2008) Early donor management
increases the retrieval rate of lungs for transplantation. Ann
Thorac Surg 85(1):278–286
20. Wood KE, Becker BN, McCartney JG, D'Alessandro AM,
Coursin DB (2004) Care of the potential organ donor. N Engl J
Med 351(26):2730–2739
21. Kumar TKS, Mathis C, Sathanandam S, Zurakowski D,
Subramanian S, Allen J et al (2017) Effect of thyroid hormone
on cardiac function following orthotopic heart transplantation in
piglets. Pediatr Transplant 21(6)
22. Novitzky D, Mi Z, Collins JF, Cooper DK (2015) Increased pro-
curement of thoracic donor organs after thyroid hormone therapy.
Semin Thorac Cardiovasc Surg 27(2):123–132
23. Schipper DA, Marsh KM, Ferng AS, Duncker DJ, Laman JD,
Khalpey Z (2016) The critical role of bioenergetics in donor car-
diac allograft preservation. J Cardiovasc Transl Res 9(3):176–183
24. Belzer FO, Southard JH (1988) Principles of solid-organ preser-
vation by cold storage. Transplantation. 45(4):673–676
25. Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, Kobashigawa
J (2000) The use of donor hearts with left ventricular hypertrophy.
J Heart Lung Transplant 19(5):496–503
26. Anaya-Prado R, Delgado-Vazquez JA (2008) Scientific basis of
organ preservation. Curr Opin Organ Transplant 13(2):129–134
27. Vigne P, Frelin C, Lazdunski M (1985) The Na+/H+ exchanger in
eukaryotic cells: biochemical and pharmacological properties and
physiological role. Biochimie. 67(1):129–135
28. Karmazyn M, Gan XT, Humphreys RA, Yoshida H, Kusumoto K
(1999) The myocardial Na(+)-H(+) exchange: structure, regula-
tion, and its role in heart disease. Circ Res 85(9):777–786
29. Marasco SF, Kras A, Schulberg E, Vale M, Lee GA (2012) Impact
of warm ischemia time on survival after heart transplantation.
Transplant Proc 44(5):1385–1389
30. Braunwald E, Kloner RA (1985) Myocardial reperfusion: a
double-edged sword? J Clin Invest 76(5):1713–1719
31. MorcianoG, BonoraM,CampoG,Aquila G, Rizzo P, Giorgi C et al
(2017)Mechanistic role of mPTP in ischemia-reperfusion injury. In:
Santulli G (ed)Mitochondrial dynamics in cardiovascular medicine.
Springer International Publishing, Cham, pp 169–189
32. Penna C, Perrelli MG, Pagliaro P (2013) Mitochondrial pathways,
permeability transition pore, and redox signaling in
cardioprotection: therapeutic implications. Antioxid Redox
Signal 18(5):556–599
33. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D,
Ovize M (2005) Postconditioning inhibits mitochondrial perme-
ability transition. Circulation. 111(2):194–197
34. Upadhaya S, Madala S, Baniya R, Subedi SK, Saginala K,
BachuwaG (2017) Impact of cyclosporine A use in the prevention
of reperfusion injury in acute myocardial infarction: a meta-anal-
ysis. Cardiol J 24(1):43–50
35. Hausenloy D, Wynne A, Duchen M, Yellon D (2004) Transient mi-
tochondrial permeability transition pore opening mediates
preconditioning-induced protection. Circulation. 109(14):1714–1717
36. Birnbaum Y, Hale SL, Kloner RA (1997) Ischemic precondition-
ing at a distance: reduction of myocardial infarct size by partial
reduction of blood supply combined with rapid stimulation of the
gastrocnemius muscle in the rabbit. Circulation 96(5):1641–1646
37. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA,
Downey JM (1991) Protection against infarction afforded by pre-
conditioning is mediated by A1 adenosine receptors in rabbit
heart. Circulation. 84(1):350–356
38. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N,
Pasa S et al (2013) Cardioprotective and prognostic effects of
remote ischaemic preconditioning in patients undergoing coronary
artery bypass surgery: a single-centre randomised, double-blind,
controlled trial. Lancet (London, England) 382(9892):597–604
39. Benstoem C, Stoppe C, Liakopoulos OJ, Ney J, Hasenclever D,
Meybohm P et al (2017) Remote ischaemic preconditioning for
coronary artery bypass grafting (with or without valve surgery).
Cochrane Database Syst Rev 5:Cd011719
40. D'Ascenzo F, Cavallero E, Moretti C, Omede P, Sciuto F, Rahman
IA et al (2012) Remote ischaemic preconditioning in coronary
artery bypass surgery: a meta-analysis. Heart. 98(17):1267–1271
41. HausenloyDJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar
S et al (2015) Remote ischemic preconditioning and outcomes of
cardiac surgery. N Engl J Med 373(15):1408–1417
42. Pierce B, Bole I, Patel V, Brown DL. Clinical outcomes of remote
ischemic preconditioning prior to cardiac surgery: a meta-analysis
of randomized controlled trials. J Am Heart Assoc. 2017;6(2)
43. Meybohm P, Kohlhaas M, Stoppe C, Gruenewald M, Renner J,
Bein B, et al. RIPHeart (Remote Ischemic Preconditioning for
Heart Surgery) study: myocardial dysfunction, postoperative
neurocognitive dysfunction, and 1 year follow-up. J Am Heart
Assoc. 2018;7(7)
44. Kleinbongard P, Neuhauser M, Thielmann M, Kottenberg E,
Peters J, Jakob H et al (2016) Confounders of cardioprotection
by remote ischemic preconditioning in patients undergoing coro-
nary artery bypass grafting. Cardiology. 133(2):128–133
45. Konstantinov IE, Li J, Cheung MM, Shimizu M, Stokoe J,
Kharbanda RK et al (2005) Remote ischemic preconditioning of
the recipient reduces myocardial ischemia-reperfusion injury of
the denervated donor heart via a Katp channel-dependent mecha-
nism. Transplantation. 79(12):1691–1695
46. Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai MZ
(2002) Influence of diabetic state and that of different sulfonyl-
ureas on the size of myocardial infarction with and without ische-
mic preconditioning in rabbits. Exp Clin Endocrinol Diabetes
110(5):212–218
47. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka
K et al (2001) Diabetes mellitus prevents ischemic precondition-
ing in patients with a first acute anterior wall myocardial infarc-
tion. J Am Coll Cardiol 38(4):1007–1011
48. Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk
JE, Nielsen TT et al (2004) Ischaemic preconditioning does not
protect the heart in obese and lean animal models of type 2 diabe-
tes. Diabetologia. 47(10):1716–1721
49. Crisostomo PR, Wang M, Wairiuko GM, Terrell AM, Meldrum
DR (2006) Postconditioning in females depends on injury sever-
ity. J Surg Res 134(2):342–347
50. Heinen A, Behmenburg F, Aytulun A, Dierkes M, Zerbin L,
Kaisers W et al (2018) The release of cardioprotective humoral
factors after remote ischemic preconditioning in humans is age-
and sex-dependent. J Transl Med 16(1):112
51. Moolman JA, Genade S, Tromp E, Opie LH, Lochner A (1997)
Ischaemic preconditioning does not protect hypertrophied myo-
cardium against ischaemia. S Afr Med J = Suid-Afrikaanse
tydskrif vir geneeskunde 87(Suppl 3):C151–C156
52. EbrahimZ,YellonDM,Baxter GF (2007) Ischemic preconditioning
is lost in aging hypertensive rat heart: independent effects of aging
and longstanding hypertension. Exp Gerontol 42(8):807–814
Heart Fail Rev
53. Bartling B, Friedrich I, Silber RE, Simm A (2003) Ischemic pre-
conditioning is not cardioprotective in senescent human myocar-
dium. Ann Thorac Surg 76(1):105–111
54. Nichols CG, Lederer WJ (1990) The role of ATP in energy-
deprivation contractures in unloaded rat ventricular myocytes.
Can J Physiol Pharmacol 68(2):183–194
55. Schluter KD, Jakob G, Ruiz-Meana M, Garcia-Dorado D, Piper
HM (1996) Protection of reoxygenated cardiomyocytes against
osmotic fragility by nitric oxide donors. Am J Phys 271(2 Pt 2):
H428–H434
56. Piper HM, Abdallah Y, Schäfer C (2004) The first minutes of
reperfusion: a window of opportunity for cardioprotection.
Cardiovasc Res 61(3):365–371
57. Inserte J, Garcia-Dorado D, Hernando V, Soler-Soler J (2005)
Calpain-mediated impairment of Na+/K+-ATPase activity during
early reperfusion contributes to cell death after myocardial ische-
mia. Circ Res 97(5):465–473
58. Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte
J, Agulló L, Cabestrero A (2006) The end-effectors of precondi-
tioning protection against myocardial cell death secondary to is-
chemia–reperfusion. Cardiovasc Res 70(2):274–285
59. Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M (2004)
Gap junction-mediated spread of cell injury and death during
myocardial ischemia-reperfusion. Cardiovasc Res 61(3):386–401
60. White CW, Messer SJ, Large SR, Conway J, Kim DH,
Kutsogiannis DJ et al (2018) Transplantation of hearts donated
after circulatory death. Front Cardiovasc Med 5:8
61. White CW, Lillico R, Sandha J, Hasanally D, Wang F, Ambrose E
et al (2016) Physiologic changes in the heart following cessation
of mechanical ventilation in a porcine model of donation after
circulatory death: implications for cardiac transplantation. Am J
Transplant Off J Am Soc Transplant Am Soc Transplant Surg
16(3):783–793
62. Manara AR, Murphy PG, O'Callaghan G (2012) Donation after
circulatory death. Br J Anaesth 108(suppl_1):i108–ii21
63. Page A, Messer S, Large SR (2018) Heart transplantation from
donation after circulatory determined death. Ann Cardiothorac
Surg 7(1):75–81
64. Chan JL, Kobashigawa JA, Aintablian TL, Li Y, Perry PA, Patel
JK et al (2017) Vasoplegia after heart transplantation: outcomes at
1 year†. Interact Cardiovasc Thorac Surg 25(2):212–217
65. Omar S, Zedan A, Nugent K (2015) Cardiac vasoplegia syn-
drome: pathophysiology, risk factors and treatment. Am J Med
Sci 349(1):80–88
66. Rylski B, Berchtold-HerzM, OlschewskiM, ZehW, Schlensak C,
Siepe M et al (2010) Reducing the ischemic time of donor hearts
will decrease morbidity and costs of cardiac transplantations☆.
Interact Cardiovasc Thorac Surg 10(6):945–947
67. Stobierska-Dzierzek B, Awad H,Michler RE (2001) The evolving
management of acute right-sided heart failure in cardiac transplant
recipients. J Am Coll Cardiol 38(4):923–931
68. Russo MJ, Chen JM, Sorabella RA, Martens TP, Garrido M,
Davies RR et al (2007) The effect of ischemic time on survival
after heart transplantation varies by donor age: an analysis of the
United Network for Organ Sharing database. J Thorac Cardiovasc
Surg 133(2):554–559
69. Loebe M, Potapov EV, Hummel M, Weng Y, Bocksch W, Hetzer
R (2000) Medium-term results of heart transplantation using older
donor organs. J Heart Lung Transplant 19(10):957–963
70. Lietz K, John R, Mancini DM, Edwards NM (2004) Outcomes in
cardiac transplant recipients using allografts from older donors
versus mortality on the transplant waiting list: implications for
donor selection criteria. J Am Coll Cardiol 43(9):1553–1561
71. Blanche C, Kamlot A, Blanche DA, Kearney B, Magliato KE,
Czer LSC et al (2002) Heart transplantation with donors fifty years
of age and older. J Thorac Cardiovasc Surg 123(4):810–815
72. Potapov EV, Loebe M, Hubler M,Musci M, Hummel M, Weng Y
et al (1999) Medium-term results of heart transplantation using
donors over 63 years of age. Transplantation. 68(12):1834–1838
73. Croome KP, Dan S, Roberto HA, Adams PC, Alan T, Natasha C
(2014) Female donor to male recipient gender discordance results
in inferior graft survival: a prospective study of 1,042 liver trans-
plants. J Hepatobiliary Pancreat Sci 21(4):269–274
74. Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van
Houwelingen HC, Apperley J et al (2001) Female donors influ-
ence transplant-related mortality and relapse incidence in male
recipients of sibling blood and marrow transplants. Hematol J
2(6):363–370
75. Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U
et al (2015) Can a female donor for a male recipient decrease the
relapse rate for patients with acute myeloid leukemia treated with
allogeneic hematopoietic stem cell transplantation? Biol Blood
Marrow Transplant 21(4):713–719
76. Yamani MH, Lauer MS, Starling RC, Pothier CE, Tuzcu EM,
Ratliff NB et al (2004) Impact of donor spontaneous intracranial
hemorrhage on outcome after heart transplantation. Am J
Transplant 4(2):257–261
77. Shanlin RJ, Sole MJ, Rahimifar M, Tator CH, Factor SM (1988)
Increased intracranial pressure elicits hypertension, increased
sympathetic activity, electrocardiographic abnormalities and myo-
cardial damage in rats. J Am Coll Cardiol 12(3):727–736
78. Tsai FC,Marelli D, Bresson J, Gjertson D, Kermani R, Patel J et al
(2002) Use of hearts transplanted from donors with atraumatic
intracranial bleeds. J Heart Lung Transplant 21(6):623–628
79. Lima B, Rajagopal K, Petersen RP, Shah AS, Soule B, Felker GM
et al (2006) Marginal cardiac allografts do not have increased
primary graft dysfunction in alternate list transplantation.
Circulation. 114(1 Suppl):I27–I32
80. Goland S, Czer LS, Kass RM, Siegel RJ, Mirocha J, De Robertis
MA et al (2008) Use of cardiac allografts with mild and moderate
left ventricular hypertrophy can be safely used in heart transplanta-
tion to expand the donor pool. J AmColl Cardiol 51(12):1214–1220
81. Felker GM, Milano CA, Yager JE, Hernandez AF, Blue L,
Higginbotham MB et al (2005) Outcomes with an alternate list
strategy for heart transplantation. J Heart Lung Transplant 24(11):
1781–1786
82. Pinzon OW, Stoddard G, Drakos SG, Gilbert EM, Nativi JN,
Budge D et al (2011) Impact of donor left ventricular hypertrophy
on survival after heart transplant. Am J Transplant Off J Am Soc
Transplant Am Soc Transplant Surg 11(12):2755–2761
83. Aziz S, Soine LA, Lewis SL, Kruse AP, Levy WC et al (1997)
Donor left ventricular hypertrophy increases risk for early graft
failure. Transpl Int 10(6):446–450
84. Kuppahally SS, Valantine HA, Weisshaar D, Parekh H, Hung YY,
Haddad F et al (2007) Outcome in cardiac recipients of donor
hearts with increased left ventricular wall thickness. Am J
Transplant Off J Am Soc Transplant Am Soc Transplant Surg
7(10):2388–2395
85. Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD,
Kirk R et al (2010) The Registry of the International Society for
Heart and Lung Transplantation: twenty-seventh official adult
heart transplant report—2010. J Heart Lung Transplant 29(10):
1089–1103
86. Dunn FG, Pringle SD (1987) Left ventricular hypertrophy and
myocardial ischemia in systemic hypertension. Am J Cardiol
60(17):19–22
87. García Sáez D, Zych B, Sabashnikov A, Bowles CT, De Robertis
F, Mohite PN et al (2014) Evaluation of the organ care system in
heart transplantation with an adverse donor/recipient profile. Ann
Thorac Surg 98(6):2099–2106
88. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M,
Desai S et al (2010) The International Society of Heart and Lung
Heart Fail Rev
Transplantation Guidelines for the care of heart transplant recipi-
ents. J Heart Lung Transplant 29(8):914–956
89. Movahed A, ReevesWC,Mehta PM, GillilandMG,Mozingo SL,
Jolly SR (1994) Norepinephrine-induced left ventricular dysfunc-
tion in anesthetized and conscious, sedated dogs. Int J Cardiol
45(1):23–33
90. D'Alessandro C, Golmard JL, Barreda E, Laali M, Makris R, Luyt
CE et al (2011) Predictive risk factors for primary graft failure
requiring temporary extra-corporeal membrane oxygenation sup-
port after cardiac transplantation in adults. Eur J Cardiothorac Surg
40(4):962–969
91. Santise G, D'Ancona G, Falletta C, Pirone F, Sciacca S, Turrisi M
et al (2009) Donor pharmacological hemodynamic support is as-
sociated with primary graft failure in human heart transplantation.
Interact Cardiovasc Thorac Surg 9(3):476–479
92. Segovia J, Cosio MD, Barcelo JM, Bueno MG, Pavia PG, Burgos
R et al (2011) RADIAL: a novel primary graft failure risk score in
heart transplantation. J Heart Lung Transplant 30(6):644–651
93. McKeown DW, Bonser RS, Kellum JA (2012) Management of
the heartbeating brain-dead organ donor. Br J Anaesth
108(suppl_1):i96–i107
94. Yoshioka T, Sugimoto H, Uenishi M, Sakamoto T, Sadamitsu D,
Sakano T et al (1986) Prolonged hemodynamic maintenance by
the combined administration of vasopressin and epinephrine in
brain death: a clinical study. Neurosurgery. 18(5):565–567
95. Venkateswaran RV, Steeds RP, Quinn DW, Nightingale P, Wilson
IC, Mascaro JG et al (2009) The haemodynamic effects of adjunc-
tive hormone therapy in potential heart donors: a prospective ran-
domized double-blind factorially designed controlled trial. Eur
Heart J 30(14):1771–1780
96. Hong KN, Iribarne A, Worku B, Takayama H, Gelijns AC, Naka
Yet al (2011) Who is the high-risk recipient? Predicting mortality
after heart transplant using pretransplant donor and recipient risk
factors. Ann Thorac Surg 92(2):520–527
97. Young JB, Hauptman PJ, Naftel DC, Ewald G, Aaronson K, Dec
GW et al (2001) Determinants of early graft failure following
cardiac transplantation, a 10-year, multi-institutional, multivari-
able analysis. J Heart Lung Transplant 20(2):212
98. Truby LK, Takeda K, Topkara VK, Takayama H, Garan AR,
Yuzefpolskaya M et al (2018) Risk of severe primary graft dys-
function in patients bridged to heart transplantation with
continuous-flow left ventricular assist devices. J Heart Lung
Transplant 37(12):1433–1442
99. Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED,
Myers SL et al (2017) Eighth annual INTERMACS report: special
focus on framing the impact of adverse events. J Heart Lung
Transplant 36(10):1080–1086
100. Foroutan F, Ross HJ (2019) Primary graft dysfunction: the devil is
in the details. Transplantation. 103(2):229–230
101. Foroutan F, Alba AC, Guyatt G, Duero Posada J, Ng Fat Hing N,
Arseneau E et al (2018) Predictors of 1-year mortality in heart
transplant recipients: a systematic review and meta-analysis.
Heart. 104(2):151–160
102. Taghavi S, Jayarajan SN, Wilson LM, Komaroff E, Testani JM,
Mangi AA (2013) Cardiac transplantation can be safely performed
using selected diabetic donors. J Thorac Cardiovasc Surg 146(2):
442–447
103. Singh TP, Almond CS, SemigranMJ, Piercey G, Gauvreau K (2012)
Risk prediction for early in-hospital mortality following heart trans-
plantation in the United States. Circ Heart Fail 5(2):259–266
104. Yeom SY, Hwang HY, Oh S-J, Cho H-J, Lee H-Y, Kim K-B
(2013) Heart transplantation in the elderly patients: midterm re-
sults. Korean J Thorac Cardiovasc Surg 46(2):111–116
105. Bull DA, Karwande SV, Hawkins JA, Neumayer LA, Taylor DO,
Jones KW et al (1996) Long-term results of cardiac transplantation
in patients older than sixty years. UTAH Cardiac Transplant
Program. J Thorac Cardiovasc Surg 111(2):423–427 discussion 7-8
106. Tjang YS, van der Heijden GJ, Tenderich G, Korfer R, Grobbee
DE (2008) Impact of recipient’s age on heart transplantation out-
come. Ann Thorac Surg 85(6):2051–2055
107. Morales D, Williams E, John R (2010) Is resternotomy in cardiac
surgery still a problem?☆. Interact Cardiovasc Thorac Surg 11(3):
277–286
108. Kuralay E, Bolcal C, Cingoz F, Gunay C, Yildirim V, Kilic S et al
(2004) Cardiac reoperation by Carpentier bicaval femoral venous
cannula: GATA experience. Ann Thorac Surg 77(3):977–981 dis-
cussion 82
109. Still S, Shaikh AF, Qin H, Felius J, Jamil AK, Saracino G et al
(2018) Reoperative sternotomy is associated with primary graft
dysfunction following heart transplantation. Interact Cardiovasc
Thorac Surg
110. Awad M, Czer LS, Mirocha J, Ruzza A, Rafiei M, Reich H et al
(2015) Prior sternotomy increases the mortality and morbidity of
adult heart transplantation. Transplant Proc 47(2):485–497
111. Kansara P, Czer L, Awad M, Arabia F, Mirocha J, De Robertis M
et al (2014) Heart transplantation with and without prior
sternotomy: analysis of the United Network for Organ Sharing
database. Transplant Proc 46(1):249–255
112. Santangeli P, Rame JE, Birati EY, Marchlinski FE (2017)
Management of ventricular arrhythmias in patients with advanced
heart failure. J Am Coll Cardiol 69(14):1842–1860
113. Macdonald P, Hackworthy R, Keogh A, Sivathasan C, Chang V,
Spratt P (1991) The effect of chronic amiodarone therapy before
transplantation on early cardiac allograft function. J Heart Lung
Transplant 10(5 Pt 1):743–748 discussion 8-9
114. Chelimsky-Fallick C, Middlekauff HR, Stevenson WG,
Kobashigawa J, Saxon LA, Moriguchi J et al (1992)
Amiodarone therapy does not compromise subsequent heart
transplantation. J Am Coll Cardiol 20(7):1556–1561
115. Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C,
Gleissner CA et al (2016) Long-term use of amiodarone before
heart transplantation significantly reduces early post-transplant
atrial fibrillation and is not associated with increased mortality
after heart transplantation. Drug Des Devel Ther 10:677–686
116. Wright M, Takeda K, Mauro C, Jennings D, Kurlansky P, Han J
et al (2017) Dose-dependent association between amiodarone and
severe primary graft dysfunction in orthotopic heart transplanta-
tion. J Heart Lung Transplant 36(11):1226–1233
117. Chin C, Feindel C, Cheng D (1999) Duration of preoperative
amiodarone treatment may be associated with postoperative hos-
pital mortality in patients undergoing heart transplantation. J
Cardiothorac Vasc Anesth 13(5):562–566
118. Halazun KJ, Al-Mukhtar A, Aldouri A,Willis S, Ahmad N (2007)
Warm ischemia in transplantation: search for a consensus defini-
tion. Transplant Proc 39(5):1329–1331
119. Squiers JJ, Saracino G, Chamogeorgakis T, MacHannaford JC,
Rafael AE, Gonzalez-Stawinski GV et al (2017) Application of
the International Society for Heart and Lung Transplantation
(ISHLT) criteria for primary graft dysfunction after cardiac trans-
plantation: outcomes from a high-volume centredagger. Eur J
Cardiothorac Surg 51(2):263–270
120. Banner NR, Thomas HL, Curnow E, Hussey JC, Rogers CA,
Bonser RS (2008) The importance of cold and warm cardiac is-
chemia for survival after heart transplantation. Transplantation.
86(4):542–547
121. Wong G, Teixeira-Pinto A, Chapman JR, Craig JC, Pleass H,
McDonald S et al (2017) The impact of total ischemic time, donor
age and the pathway of donor death on graft outcomes after de-
ceased donor kidney transplantation. Transplantation. 101(6):
1152–1158
Heart Fail Rev
122. Salis S,Mazzanti VV,Merli G, Salvi L, Tedesco CC, Veglia F et al
(2008) Cardiopulmonary bypass duration is an independent pre-
dictor of morbidity and mortality after cardiac surgery. J
Cardiothorac Vasc Anesth 22(6):814–822
123. Kirklin JW (1980) Open-heart surgery at the Mayo Clinic. The
25th anniversary. Mayo Clin Proc 55(5):339–341
124. Anselmi A, Abbate A, Girola F, Nasso G, Biondi-Zoccai GG,
Possati G et al (2004) Myocardial ischemia, stunning, inflamma-
tion, and apoptosis during cardiac surgery: a review of evidence.
Eur J Cardiothorac Surg 25(3):304–311
125. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L,
Angelini GD (2007) Increased mortality, postoperative morbidity,
and cost after red blood cell transfusion in patients having cardiac
surgery. Circulation. 116(22):2544–2552
126. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop
FD et al (2006) Morbidity and mortality risk associated with red
blood cell and blood-component transfusion in isolated coronary
artery bypass grafting. Crit Care Med 34(6):1608–1616
127. Kuduvalli M, Oo AY, Newall N, Grayson AD, Jackson M,
Desmond MJ et al (2005) Effect of peri-operative red blood cell
transfusion on 30-day and 1-year mortality following coronary
artery bypass surgery. Eur J Cardiothorac Surg 27(4):592–598
128. Reed RM, Netzer G, Hunsicker L, Mitchell BD, Rajagopal K,
Scharf S et al (2014) Cardiac size and sex-matching in heart trans-
plantation: size matters in matters of sex and the heart. JACC
Heart Fail 2(1):73–83
129. Smits JM, Vanhaecke J, Haverich A, de Vries E, Smith M,
Rutgrink E et al (2003) Three-year survival rates for all consecu-
tive heart-only and lung-only transplants performed in
Eurotransplant, 1997-1999. Clin Transpl:89–100
130. Patel ND, Weiss ES, Nwakanma LU, Russell SD, Baumgartner
WA, Shah AS et al (2008) Impact of donor-to-recipient weight
ratio on survival after heart transplantation: analysis of the
United Network for Organ Sharing Database. Circulation.
118(14 Suppl):S83–S88
131. Weiss ES, Allen JG, Patel ND, Russell SD, Baumgartner WA,
Shah AS et al (2009) The impact of donor-recipient sex matching
on survival after orthotopic heart transplantation: analysis of 18
000 transplants in the modern era. Circ Heart Fail 2(5):401–408
132. Stehlik J, Feldman DS, Brown RN, VanBakel AB, Russel SD,
Ewald GA et al (2010) Interactions among donor characteristics
influence post-transplant survival: a multi-institutional analysis. J
Heart Lung Transplant 29(3):291–298
133. Jayarajan SN, Taghavi S, Komaroff E, Mangi AA (2013) Impact
of low donor to recipient weight ratios on cardiac transplantation. J
Thorac Cardiovasc Surg 146(6):1538–1543
134. Murphy K, Kransdorf EP, Wilansky S, Pajaro OE, Steidley DE
(2016) Impact of size mismatch on heart transplant outcomes. J
Heart Lung Transplant 35(4):S214–S2S5
135. Kertesz NJ, Gajarski RJ, Towbin JA, Geva T (1995) Effect of
donor-recipient size mismatch on left ventricular remodeling after
pediatric orthotopic heart transplantation. Am J Cardiol 76(16):
1167–1172
136. Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF
receptor superfamilies: integrating mammalian biology. Cell.
104(4):487–501
137. Cui X, Chang L, Li Y, Lv Q, Wang F, Lin Yet al (2018) Trivalent
soluble TNF receptor, a potent TNF-alpha antagonist for the treat-
ment collagen-induced arthritis. Sci Rep 8(1):7327
138. Mukhopadhyay S, Hoidal JR, Mukherjee TK (2006) Role of
TNFα in pulmonary pathophysiology. Respir Res 7(1):125
139. Sack MN (2002) Tumor necrosis factor-α in cardiovascular biol-
ogy and the potential role for anti-tumor necrosis factor-α therapy
in heart disease. Pharmacol Ther 94(1):123–135
140. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990)
Elevated circulating levels of tumor necrosis factor in severe
chronic heart failure. N Engl J Med 323(4):236–241
141. Birks EJ, Burton PB, Owen V, Mullen AJ, Hunt D, Banner NR
et al (2000) Elevated tumor necrosis factor-alpha and interleukin-6
in myocardium and serum of malfunctioning donor hearts.
Circulation 102(19 Suppl 3):Iii352–Iii358
142. Tatham KC, O'Dea KP, Romano R, Donaldson HE, Wakabayashi
K, Patel BV et al (2018) Intravascular donor monocytes play a
central role in lung transplant ischaemia-reperfusion injury.
Thorax. 73(4):350–360
143. Schnickel GT, Ross DJ, Beygui R, Shefizadeh A, Laks H, Saggar
R et al (2006) Modified reperfusion in clinical lung transplanta-
tion: the results of 100 consecutive cases. J Thorac Cardiovasc
Surg 131(1):218–223
144. Venkateswaran RV, Dronavalli V, Lambert PA, Steeds RP,Wilson IC,
Thompson RD et al (2009) The proinflammatory environment in
potential heart and lung donors: prevalence and impact of donor man-
agement and hormonal therapy. Transplantation. 88(4):582–588
145. Braulio R, Sanches MD, Teixeira Junior AL, Costa PHN, Moreira
MCV, Rocha MA et al (2016) Associated clinical and laboratory
markers of donor on allograft function after heart transplant. Braz J
Cardiovasc Surg 31(2):89–97
146. Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation,
immunity, and disease. Cold Spring Harb Perspect Biol 6(10):
a016295
147. Fontes JA, Rose NR,Čiháková D (2015) The varying faces of IL-6:
from cardiac protection to cardiac failure. Cytokine. 74(1):62–68
148. Plenz G, Eschert H, Erren M, Wichter T, BöhmM, Flesch M et al
(2002) The interleukin-6/interleukin-6-receptorsystem is activated
in donor hearts. J Am Coll Cardiol 39(9):1508–1512
149. Moreno I, Vicente R, Ramos F, Vicente JL, Barbera M (2007)
Determination of interleukin-6 in lung transplantation: association
with primary graft dysfunction. Transplant Proc 39(7):2425–2426
150. KukielkaGL, Smith CW,ManningAM,Youker KA,Michael LH,
Entman ML (1995) Induction of interleukin-6 synthesis in the
myocardium. Potential role in postreperfusion inflammatory inju-
ry. Circulation. 92(7):1866–1875
151. GwechenbergerM,Mendoza LH, Youker KA, Frangogiannis NG,
Smith CW, Michael LH et al (1999) Cardiac myocytes produce
interleukin-6 in culture and in viable border zone of reperfused
infarctions. Circulation. 99(4):546–551
152. Jin M, Khan AI (2010) Procalcitonin: uses in the clinical labora-
tory for the diagnosis of sepsis. Lab Med 41(3):173–177
153. Sandkovsky U, Kalil AC, Florescu DF (2015) The use and value
of procalcitonin in solid organ transplantation. Clin Transpl 29(8):
689–696
154. Yu XY, Wang Y, Zhong H, Dou QL, Song YL, Wen H (2014)
Diagnostic value of serum procalcitonin in solid organ transplant
recipients: a systematic review and meta-analysis. Transplant Proc
46(1):26–32
155. Madershahian N, Wittwer T, Strauch J, Wippermann J,
Rahmanian P, Franke UF et al (2008) Kinetic of procalcitonin in
the early postoperative course following heart transplantation. J
Card Surg 23(5):468–473
156. Wagner FD, Jonitz B, Potapov EV, Qedra N, Wegscheider K,
Abraham K et al (2001) Procalcitonin, a donor-specific predictor
of early graft failure-related mortality after heart transplantation.
Circulation. 104(12 Suppl 1):I192–I196
157. van Ree RM, de Vries AP, OterdoomLH, SeelenMA, Gansevoort
RT, Schouten JP et al (2009) Plasma procalcitonin is an indepen-
dent predictor of graft failure late after renal transplantation.
Transplantation. 88(2):279–287
158. Eyraud D, Ben Ayed S, Tanguy ML, Vezinet C, Siksik JM,
Bernard M et al (2008) Procalcitonin in liver transplantation: are
Heart Fail Rev
high levels due to donors or recipients? Crit Care (London,
England) 12(4):R85
159. Sammons C, Doligalski CT (2014) Utility of procalcitonin as a
biomarker for rejection and differentiation of infectious complica-
tions in lung transplant recipients. Ann Pharmacother 48(1):116–
122
160. Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G et al (2013)
Neutrophil to lymphocyte ratio and cardiovascular diseases: a re-
view. Expert Rev Cardiovasc Ther 11(1):55–59
161. Ucar FM, Acar B, Gul M, Ozeke O, Aydogdu S (2016) The asso-
ciation between platelet/lymphocyte ratio and coronary artery dis-
ease severity in asymptomatic low ejection fraction patients.
Korean Circ J 46(6):821–826
162. Huang WM, Cheng HM, Huang CJ, Guo CY, Lu DY, Lee CW
et al (2017) Hemographic indices are associated with mortality in
acute heart failure. Sci Rep 7(1):17828
163. Yost G, Ibrahim K, Tatooles A, Bhat G (2017) Longitudinal neu-
trophil to lymphocyte ratio assessment after left ventricular assist
device implantation. J Heart Lung Transplant 36(4):S349
164. Seropian IM, Romeo FJ, Pizarro R, Vulcano NO, Posatini RA,
Marenchino RG et al (2018) Neutrophil-to-lymphocyte ratio and
platelet-to-lymphocyte ratio as predictors of survival after heart
transplantation. ESC Heart Fail 5(1):149–156
165. Hogendorf P, Suska A, Skulimowski A, Rut J, Grochowska M,
Wencel A et al (2018) Neutrophil-lymphocyte ratio and creatinine
reduction ratio predict good early graft function among adult ca-
daveric donor renal transplant recipients. Single institution series.
Polski przeglad chirurgiczny 90(2):28–33
166. Yost G, Bhat G, Pappas P, Tatooles A (2018) The neutrophil to
lymphocyte ratio in patients supported with extracorporeal mem-
brane oxygenation. Perfusion. 267659118772455
167. Sharma S, Jackson PG, Makan J (2004) Cardiac troponins. J Clin
Pathol 57(10):1025–1026
168. Dronavalli VB, Banner NR, Bonser RS (2010) Assessment of the
potential heart donor: a role for biomarkers? J Am Coll Cardiol
56(5):352–361
169. Riou B, Dreux S, Roche S, Arthaud M, Goarin JP, Léger P et al
(1995) Circulating cardiac troponin T in potential heart transplant
donors. Circulation. 92(3):409–414
170. Potapov EV, Wagner FD, Loebe M, Ivanitskaia EA, Müller C,
Sodian R et al (2003) Elevated donor cardiac troponin T and
procalcitonin indicate two independent mechanisms of early graft
failure after heart transplantation. Int J Cardiol 92(2):163–167
171. Vijay P, Scavo VA, Morelock RJ, Sharp TG, Brown JW (1998)
Donor cardiac troponin T: a marker to predict heart transplant
rejection. Ann Thorac Surg 66(6):1934–1939
172. Potapov EV, Ivanitskaia EA, Loebe M, Mückel M, Müller C,
Sodian R et al (2001) Value of cardiac troponin I and T for selec-
tion of heart donors and as predictors of early graft failure.
Transplantation. 71(10):1394–1400
173. Deibert E, Aiyagari V, Diringer MN (2000) Reversible left ven-
tricular dysfunction associated with raised troponin I after sub-
arachnoid haemorrhage does not preclude successful heart trans-
plantation. Heart. 84(2):205–207
174. Deibert E, Barzilai B, Braverman AC, Edwards DF, Aiyagari V,
Dacey R et al (2003) Clinical significance of elevated troponin I
levels in patients with nontraumatic subarachnoid hemorrhage. J
Neurosurg 98(4):741–746
175. Boccheciampe N, Audibert G, Rangeard O, Charpentier C, Perrier
JF, Lalot JM et al (2009) Serum troponin Ic values in organ donors
are related to donor myocardial dysfunction but not to graft dys-
function or rejection in the recipients. Int J Cardiol 133(1):80–86
176. Khush KK, Menza RL, Babcock WD, Zaroff JG (2007) Donor
cardiac troponin I levels do not predict recipient survival after car-
diac transplantation. J Heart Lung Transplant 26(10):1048–1053
177. Madan S, Saeed O, Shin J, Sims D, Goldstein D, Pina I, et al.
Donor troponin and survival after cardiac transplantation: an anal-
ysis of the United Network of Organ Sharing Registry. Circ Heart
Fail. 2016;9(6)
178. SchechterMA,WatsonMJ, Feger BJ, SoutherlandKW,Mishra R,
Dibernardo LR et al (2016) Elevated cardiac troponin I in preser-
vation solution is associated with primary graft dysfunction. J
Card Fail 22(2):158–162
179. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC,
Baumann M, Pedersen F (2004) Diagnostic and prognostic eval-
uation of left ventricular systolic heart failure by plasma N-
terminal pro-brain natriuretic peptide concentrations in a large
sample of the general population. Heart. 90(3):297–303
180. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey
KR, Saito Yet al (1996) Superiority of brain natriuretic peptide as
a hormonal marker of ventricular systolic and diastolic dysfunc-
tion and ventricular hypertrophy. Hypertension (Dallas, Tex :
1979) 28(6):988–994
181. Krittayaphong R, Boonyasirinant T, Saiviroonporn P,
Thanapiboonpol P, Nakyen S, Udompunturak S (2008)
Correlation between NT-pro BNP levels and left ventricular wall
stress, sphericity index and extent of myocardial damage: a mag-
netic resonance imaging study. J Card Fail 14(8):687–694
182. Giallauria F, Cirillo P, Lucci R, Pacileo M, De Lorenzo A,
D’AgostinoM et al (2008) Left ventricular remodelling in patients
with moderate systolic dysfunction after myocardial infarction:
favourable effects of exercise training and predictive role of N-
terminal pro-brain natriuretic peptide. Eur J Cardiovasc Prev
Rehabil 15(1):113–118
183. de Lemos JA, Morrow DA (2007) Use of natriuretic peptides in
clinical decision-making for patients with non–ST-elevation acute
coronary syndromes. Am Heart J 153(4):450–453
184. Dronavalli VB, Ranasinghe AM, Venkateswaran RJ, James SR,
McCabe CJ, Wilson IC et al (2010) N-terminal pro-brain-type na-
triuretic peptide: a biochemical surrogate of cardiac function in the
potential heart donor. Eur J Cardiothorac Surg 38(2):181–186
185. Vorlat A, Conraads VM, Jorens PG, Aerts S, Van Gorp S,
Vermeulen T et al (2012) Donor B-type natriuretic peptide pre-
dicts early cardiac performance after heart transplantation. J heart
lung transplant 31(6):579–584
186. Aharinejad S, Andrukhova O, Gmeiner M, Thomas A, Aliabadi
A, Zuckermann A et al (2009) Donor serum SMARCAL1 con-
centrations predict primary graft dysfunction in cardiac transplan-
tation. Circulation. 120(11 Suppl):S198–S205
187. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL (1996)
Dimerization, DNA binding, and transactivation properties of
hypoxia-inducible factor 1. J Biol Chem 271(30):17771–17778
188. Aharinejad S, Schafer R, Krenn K, Zuckermann A, Schneider B,
Neumann F et al (2007) Donor myocardial HIF-1alpha is an inde-
pendent predictor of cardiac allograft dysfunction: a 7-year pro-
spective, exploratory study. Am J Transplant Off J Am Soc
Transplant Am Soc Transplant Surg 7(8):2012–2019
189. Loor G, Schumacker PT (2008) Role of hypoxia-inducible factor
in cell survival during myocardial ischemia-reperfusion. Cell
Death Differ 15(4):686–690
190. Amaral N, Okonko DO (2015) Mitigation of myocardial
ischemia-reperfusion injury via HIF-1alpha-frataxin signaling.
Am J Physiol Heart Circ Physiol 309(5):H728–H730
191. Giangreco N, Chen E, Zorn E, Restaino S, Colombo PC, Tatonetti
N et al (2017) Abstract 19311: identification of novel primary graft
dysfunction biomarkers using exosome proteomics. Circulation
136(Suppl 1):A19311–A1931A
192. Fine B, Chen E, Lebreton G, Restaino S, Taupin J, Zorn E et al
(2018) Pre-transplant serum exosome proteomics differentiates
right and left ventricular primary graft dysfunction. J Heart Lung
Transplant 37(4):S24
Heart Fail Rev
193. Wagner FM, Subbotina I, Deuse T,Marcsek P, Treede H, KubikM
et al (2013) Additional intraoperative blood cardioplegia to im-
prove donor heart ischemic tolerance—a single center prospective
cohort study. Thorac Cardiovasc Surg 61(S 01):OP127
194. Cerny S, Pavel P, Pirk J, Hola I, Brezina A, Sedlacek J et al (2002)
Donor myocardial protection using secondary blood cardioplegia
during heart transplantation: prospective randomized study in 100
patients. J Heart Lung Transplant 21(1):61–62
195. Morcos K, Singh S, De Das S, AlHaideri H, Hegazy Y, Dalzell J
et al (2018) Novel technique to reduce warm ischemic time during
cardiac implantation. J Heart Lung Transplant 37(4):S425
196. Habertheuer A, Kocher A, Laufer G, Andreas M, Szeto WY,
Petzelbauer P et al (2014) Cardioprotection: a review of current
practice in global ischemia and future translational perspective.
BioMed Res Int 2014:325725
197. Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U,
Soffker G et al (2007) Hemodynamic improvement following
levosimendan treatment in patients with acute myocardial infarc-
tion and cardiogenic shock. Crit Care Med 35(12):2732–2739
198. Mebazaa A, NieminenMS, Packer M, Cohen-Solal A, Kleber FX,
Pocock SJ et al (2007) Levosimendan vs dobutamine for patients
with acute decompensated heart failure: the SURVIVE random-
ized trial. JAMA. 297(17):1883–1891
199. Weis F, Beiras-Fernandez A, Kaczmarek I, Sodian R, Kur F, Weis
M et al (2009) Levosimendan: a new therapeutic option in the
treatment of primary graft dysfunction after heart transplantation.
J Heart Lung Transplant 28(5):501–504
200. Beiras-Fernandez A, Kur F, Kaczmarek I, Frisch P, Weis M,
Reichart B et al (2011) Levosimendan for primary graft failure
after heart transplantation: a 3-year follow-up. Transplant Proc
43(6):2260–2262
201. Sundberg S, Antila S, Scheinin H, Hayha M, Virtanen M, Lehtonen
L (1998) Integrated pharmacokinetics and pharmacodynamics of
the novel calcium sensitizer levosimendan as assessed by systolic
time intervals. Int J Clin Pharmacol Ther 36(12):629–635
202. Du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A (2008) A
role for the RISK pathway and KATP channels in pre- and post-
conditioning induced by levosimendan in the isolated guinea pig
heart. Br J Pharmacol 154(1):41–50
203. Papp JG, Pollesello P, Varró AF, Végh ÁS (2006) Effect of
levosimendan and milrinone on regional myocardial ischemia/
reperfusion-induced arrhythmias in dogs. J Cardiovasc
Pharmacol Ther 11(2):129–135
204. Cammarata GAAM, Weil MH, Sun S, Huang L, Fang X, Tang W
(2006) Levosimendan improves cardiopulmonary resuscitation
and survival by KATPChannel activation. J Am Coll Cardiol
47(5):1083–1085
205. Hönisch A, Theuring N, Ebner B, Wagner C, Strasser RH,
Weinbrenner C (2010) Postconditioning with levosimendan re-
duces the infarct size involving the PI3K pathway and KATP-
channel activation but is independent of PDE-III inhibition.
Basic Res Cardiol 105(2):155–167
206. Hasslacher J, Bijuklic K, Bertocchi C, Kountchev J, Bellmann R,
Dunzendorfer S et al (2011) Levosimendan inhibits release of
reactive oxygen species in polymorphonuclear leukocytes
in vitro and in patients with acute heart failure and septic shock:
a prospective observational study. Critical Care (London,
England) 15(4):R166-R
207. Nguyen TC, Kiss JE, Goldman JR, Carcillo JA (2012) The role of
plasmapheresis in critical illness. Crit Care Clin 28(3):453–vii
208. Rydberg L (2001) ABO-incompatibility in solid organ transplan-
tation. Transfusion medicine (Oxford, England) 11(4):325–342
209. Wang SS, Chou NK, Ko WJ, Chi NH, Hung SC, Hsu RB et al
(2006) Effect of plasmapheresis for acute humoral rejection after
heart transplantation. Transplant Proc 38(10):3692–3694
210. Ince V, Aydin C, Otan E, Karabulut K, Koc S, Kayaalp C et al
(2013) Comparison of plasmapheresis and molecular adsorbent
recirculating system efficacy in graft failure after living donor liver
transplantation. Transplant Proc 45(3):971–973
211. Mandal AK, King KE, Humphreys SL, Maley WR, Burdick JF,
Klein AS (2000) Plasmapheresis: an effective therapy for primary
allograft nonfunction after liver transplantation. Transplantation.
70(1):216–220
212. Chou HW, Chi NH, Lin MH, Chou NK, Tsao CI, Yu HY et al
(2012) Steroid pulse therapy combined with plasmapheresis for
clinically compromised patients after heart transplantation.
Transplant Proc 44(4):900–902
213. Chang DH, Kittleson M, Patel J, Aintablian T, Levine R, Geft D
et al (2017) (373) - Treatment of primary graft dysfunction with
plasmapheresis improves outcome. J Heart Lung Transplant 36(4,
Supplement):S147
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Heart Fail Rev
